Kuala Lumpur-based private equity firm

总部位于吉隆坡的私募股权公司

Creador

创建者

is set to acquire about 7% stake in domestic pharmaceutical company La Renon Healthcare for ₹800 crore, according to people aware of the development.

据知情人士透露，将收购国内制药公司La Renon Healthcare约7%的股份，价值800亿卢比。

The transaction values Ahmedabad-headquartered La Renon at nearly ₹11,000 crore and will see a partial stake dilution by the promoter family as well as an existing investor. Promoter Pankaj Singh and family will sell around 5%, while Peak XV Partners (formerly Sequoia Capital) will offload about 2%..

这笔交易对总部位于艾哈迈达巴德的La Renon估值接近1100亿卢比，发起人家族和现有投资者将部分减持股份。发起人潘卡杰·辛格及其家族将出售约5%的股份，而Peak XV Partners（前身为红杉资本）将减持约2%。

Following the deal, the promoter family will continue to hold about 66%, while private equity investors together will own around 34%. Current backers of La Renon include ChrysCapital, Peak XV Partners, A91 Partners and Avendus.

根据协议，创始家族将继续持有约66%的股份，而私募股权投资者将共同拥有约34%的股份。La Renon的现有支持者包括ChrysCapital、Peak XV Partners、A91 Partners和Avendus。

The latest funding marks a sharp rise in La Renon’s valuation, which stood at ₹8,000 crore in February, when Avendus Future Leaders Fund bought a 2% stake. Last year, ChrysCapital had acquired an 8% stake in a secondary transaction valuing the company at ₹6,500 crore.

最新的融资标志着拉雷农的估值急剧上升，今年2月阿文图斯未来领袖基金购买了2%的股份时，其估值为800亿卢比。去年，ChrysCapital在一笔二级交易中收购了8%的股份，对该公司的估值为650亿卢比。

Pankaj Singh, chairman and managing director of La Renon, declined to comment. Mail sent to Creador did not elicit any response until press time.

拉勒农公司董事长兼总经理潘卡杰·辛格拒绝置评。截至记者发稿，发给Creador的邮件未得到任何回复。

Live Events

现场活动

Founded in 2007 by Singh, La Renon is among India’s fastest-growing branded formulations companies with a strong presence in chronic therapies, particularly nephrology. It has also built a sizeable presence in central nervous system (CNS), gastroenterology, gynaecology and cardio-diabetology segments..

成立于 2007 年，由辛格创立的 La Renon 是印度增长最快的仿制药公司之一，在慢性病治疗领域，尤其是肾病学方面，拥有强大的影响力。它在中枢神经系统 (CNS)、胃肠病学、妇科学和心脏糖尿病学领域也建立了可观的影响力。

For FY25, La Renon reported

对于25财年，La Renon报告称

₹1640

₹1640

crore in revenue and

千万的收入和

₹330

₹330

crore in EBITDA, and is projected to close the current fiscal with revenues of ₹2,000 crore and EBITDA of ₹450 crore, sources said. While domestic formulations drive its business, exports account for 40-45% of sales.

息税折旧摊销前利润 (EBITDA) 达到 crore 千万卢比，并预计在本财年结束时营收将达到 200 亿卢比，EBITDA 为 4.5 亿卢比，消息人士透露。虽然国内配方药是其业务的主要驱动力，但出口占销售的 40-45%。

The company operates through subsidiaries including Stanford Laboratories (formulations), Frimline (medical foods), Enaltec Labs (API research) and Rusoma Healthcare (small-volume parenterals). Its portfolio comprises around 340 formulations.

公司通过包括斯坦福实验室（配方）、Frimline（医疗食品）、Enaltec Labs（API研究）和Rusoma Healthcare（小容量注射剂）在内的子公司开展业务。其产品组合包括约340种配方。

La Renon is also investing in capacity expansion. It is setting up a new oral solid dosage plant in Rajasthan, which will ramp up production capacity from 100 million tablets/capsules per month to 400 million.

拉伦农公司也在投资扩大产能。该公司正在拉贾斯坦邦建立一个新的口服固体制剂工厂，该工厂将把生产能力从每月1亿片/粒提高到4亿片/粒。

Over the years, La Renon has attracted marquee investors. It raised ₹100 crore from Sequoia Capital in 2015, followed by ₹220 crore from A91 Partners in 2021. Discussions with Goldman Sachs for a larger ₹1,600-crore infusion had been underway earlier but did not materialise.

多年来，La Renon吸引了众多知名投资者。2015年，它从红杉资本筹集了10亿卢比，随后在2021年从A91 Partners筹集了22亿卢比。此前，与高盛就更大规模的160亿卢比注资进行了谈判，但最终未能实现。

Founded in 2011 by Brahmal Vasudevan, former general partner and managing director at ChrysCapital, Creador invests in companies across South and Southeast Asia. It has an AUM of $3 billion. Early this year, Creador closed its sixth fund at $930 million, exceeding a $750-million target.

Creador 由曾任 ChrysCapital 普通合伙人和董事总经理的 Brahmal Vasudevan 于 2011 年创立，投资于南亚和东南亚的公司，管理资产规模达 30 亿美元。今年早些时候，Creador 以 9.3 亿美元关闭了其第六只基金，超过了 7.5 亿美元的目标。

Creador has exposure in the Indian healthcare space through its investment in Corona Remedies, a drug formulation manufacturer, Paras Healthcare, a north India-focused hospital chain, and Accumax Lab Devices.

Creador通过投资印度的科罗纳制药公司（Corona Remedies）、北印度为主的医院连锁机构帕拉斯医疗集团（Paras Healthcare）以及Accumax实验室设备公司，在印度医疗保健领域有相关布局。

Add

添加

as a Reliable and Trusted News Source

作为可靠和值得信赖的新闻来源

Add Now!

立即添加！

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)